Overview
Munich, March 31, 2021 – McDermott Will & Emery advised Softhale N.V. on the sale of the company to Sino Biopharmaceutical Limited and its subsidiary, C-Lab International Limited. The purchase price amounts to US$110 million, and additional payments related to regulatory and commercial milestones. Amongst the sellers are Rhein Healthcare Investors that held a 60% majority stake in Softhale so far.
With the addition of Softhale, Sino Biopharmaceutical intends to provide a key strategic hub in Europe and expects that the company will become an important developer of innovative respiratory products for China and the global market.
Softhale is a privately held Belgium-based respiratory company focused on the development of pharmaceutical products with superior clinical performance based upon differentiated technology.
Sino Biopharmaceutical Limited and its subsidiaries are a leading innovative research and R&D-driven pharmaceutical group in China, with a business scope that covers the full industry chain of pharmaceutical R&D platforms, intelligent production and strong sales systems.
The McDermott team advising Softhale N.V. was led by partners Nadine Hartung and Stephan Rau and comprised partners Todd Finger, Nina Siewert, Steffen Woitz, counsel Jana Grieb and associate Robert Feind.
The purchase contract was subject to German law.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective — and often unexpected — solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
